Profile data is unavailable for this security.
About the company
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and healthcare companies, among others. The DocMorris division manages the mail-order business for drug retail. The Company operates in Switzerland, Germany and the Netherlands through a number of subsidiaries, such as Zur Rose Suisse AG, Zur Rose Pharma GmbH, BlueCare AG, DocMorris NV, Eurapon Pharmahandel GmbH and Vitalsana BV.
- Revenue in CHF (TTM)969.46m
- Net income in CHF-117.57m
- Incorporated1993
- Employees1.45k
- LocationDocMorris AGWalzmuehlestrasse 49FRAUENFELD 8500SwitzerlandCHE
- Phone+41 527240020
- Fax+41 527240015
- Websitehttps://www.zurrosegroup.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YSB Inc | 2.13bn | -400.44m | 616.40m | 6.31k | -- | 2.56 | -- | 0.2893 | -25.68 | -25.68 | 47.57 | 3.24 | -- | -- | -- | 2,912,810.00 | -- | -- | -- | -- | 10.26 | -- | -18.89 | -- | 1.01 | -- | 0.1002 | -- | 18.90 | -- | -114.23 | -- | -- | -- |
| Uniphar PLC | 2.49bn | 43.76m | 699.74m | 3.26k | 16.00 | 2.15 | 8.90 | 0.2807 | 0.1641 | 0.1641 | 9.35 | 1.22 | 2.13 | 12.64 | 12.71 | 782,667.70 | 3.76 | 4.12 | 6.49 | 7.24 | 15.28 | 13.61 | 1.77 | 1.87 | 0.5634 | 3.22 | 0.5338 | 10.93 | 23.30 | 12.48 | -1.69 | 38.98 | 45.53 | -- |
| NanJing Pharmaceutical Co Ltd | 6.71bn | 73.73m | 808.60m | 4.90k | 11.04 | 0.9673 | -- | 0.1206 | 0.4457 | 0.4457 | 40.51 | 5.09 | 1.63 | 8.33 | 3.33 | 10,903,610.00 | 2.22 | 2.32 | 7.44 | 8.94 | 6.04 | 6.41 | 1.36 | 1.30 | 1.13 | 2.91 | 0.6359 | 29.82 | 6.71 | 11.35 | -3.00 | 16.93 | -12.67 | 9.86 |
| Selcuk Ecza Deposu Ticaret ve Sanayi AS | 2.74bn | 6.27m | 924.45m | 6.03k | 147.45 | 2.19 | 51.38 | 0.3368 | 0.3594 | 0.3594 | 157.36 | 24.25 | 2.30 | 10.73 | 10.42 | 16,218,930.00 | 0.5255 | 3.16 | 1.41 | 8.40 | 9.38 | 9.37 | 0.2284 | 1.24 | 1.05 | -- | 0.1382 | 27.16 | 14.70 | 48.64 | -64.89 | -10.62 | 23.13 | 20.11 |
| Neuca SA | 2.68bn | 33.19m | 926.62m | 5.19k | 28.50 | 4.11 | 14.90 | 0.3457 | 32.42 | 32.42 | 2,617.05 | 224.63 | 2.38 | 7.47 | 7.13 | 2,276,477.00 | 3.21 | 3.58 | 12.45 | 13.31 | 11.07 | 10.33 | 1.35 | 1.43 | 0.4725 | 4.33 | 0.3336 | 34.59 | 5.17 | 8.79 | 6.58 | 8.95 | -3.07 | -- |
| Herbalife Ltd | 4.60bn | 124.37m | 963.30m | 9.20k | 7.75 | -- | 4.22 | 0.2094 | 1.37 | 1.37 | 50.57 | -10.39 | 1.90 | 2.25 | 58.67 | 551,586.90 | 5.14 | 11.30 | 8.68 | 18.70 | 76.80 | 78.43 | 2.70 | 6.02 | 0.7667 | 2.98 | 1.76 | 0.00 | -2.73 | 0.688 | -55.74 | -13.67 | 9.95 | -- |
| DocMorris AG | 969.46m | -117.57m | 1.08bn | 1.45k | -- | 2.04 | -- | 1.11 | -10.07 | 7.03 | 83.05 | 36.60 | 0.9863 | 11.36 | 10.50 | 667,214.10 | -11.96 | -12.92 | -15.23 | -15.74 | 20.98 | 16.84 | -12.13 | -10.87 | 1.34 | -2.39 | 0.4448 | -- | 4.13 | -4.29 | 31.29 | -- | -2.53 | -- |
| Guangxi LiuYao Group Co Ltd | 2.67bn | 111.50m | 1.16bn | 5.58k | 9.43 | 1.21 | -- | 0.4354 | 2.46 | 2.46 | 58.82 | 19.12 | 1.07 | 6.99 | 1.97 | 3,807,204.00 | 4.80 | 5.06 | 11.73 | 12.21 | 11.56 | 11.85 | 4.47 | 4.40 | 1.30 | 5.26 | 0.5434 | 29.90 | 9.23 | 12.18 | 21.11 | 9.97 | -8.63 | 6.26 |
| Sigma Healthcare Ltd | 2.05bn | 2.70m | 1.24bn | 156.00 | 321.52 | 2.29 | 61.62 | 0.6065 | 0.004 | 0.004 | 3.34 | 0.5544 | 2.68 | 11.37 | 10.52 | -- | 0.4162 | 0.5734 | 0.625 | 0.9762 | 9.17 | 9.52 | 0.1554 | 0.2022 | 1.86 | 1.59 | 0.1354 | 184.52 | -9.16 | -3.46 | 148.98 | -34.19 | -46.55 | -21.93 |
| GuangYuYuan Chinese Herbal Medicn Co Ltd | 157.84m | 15.25m | 1.54bn | 1.81k | 100.88 | 7.98 | -- | 9.75 | 0.2484 | 0.2484 | 2.57 | 3.14 | 0.4701 | 0.7661 | 1.99 | 694,836.90 | 4.96 | -2.10 | 7.42 | -3.16 | 71.43 | 69.74 | 10.56 | -6.00 | 1.16 | 12.91 | 0.1569 | -- | 13.56 | -4.53 | 136.03 | -24.78 | -58.35 | -- |
Data as of May 10 2024. Currency figures normalised to DocMorris AG's reporting currency: Swiss Franc CHF
33.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 22 Mar 2024 | 1.92m | 14.05% |
| Sands Capital Management LLCas of 31 Dec 2022 | 665.24k | 4.86% |
| Sculptor Capital LPas of 08 Jan 2024 | 424.72k | 3.10% |
| Shareholder Value Management AGas of 31 Oct 2023 | 380.00k | 2.77% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 309.95k | 2.26% |
| TFG Asset Management UK LLPas of 08 Jun 2023 | 231.97k | 1.69% |
| Credit Suisse Asset Management (Schweiz) AGas of 29 Feb 2024 | 214.23k | 1.56% |
| Z�rcher Kantonalbank (Investment Management)as of 28 Mar 2024 | 203.80k | 1.49% |
| Select Equity Group LPas of 30 Sep 2023 | 149.14k | 1.09% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 147.24k | 1.08% |
More ▼
Data from 31 Oct 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
